Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Accumulated Expenses (2016 - 2025)

Corcept Therapeutics' Other Accumulated Expenses history spans 7 years, with the latest figure at $34.0 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $34.0 million; the TTM value through Dec 2025 reached $34.0 million, changed N/A, while the annual FY2025 figure was $34.0 million, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $34.0 million at Corcept Therapeutics, up from $28.3 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $34.0 million in Q4 2025 and bottomed at $14.6 million in Q4 2022.
  • The 4-year median for Other Accumulated Expenses is $21.7 million (2023), against an average of $23.1 million.
  • The largest annual shift saw Other Accumulated Expenses soared 46.37% in 2023 before it rose 18.08% in 2024.
  • A 4-year view of Other Accumulated Expenses shows it stood at $14.6 million in 2022, then surged by 46.37% to $21.3 million in 2023, then grew by 3.01% to $22.0 million in 2024, then surged by 54.53% to $34.0 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Other Accumulated Expenses are $34.0 million (Q4 2025), $28.3 million (Q3 2025), and $22.0 million (Q2 2024).